Consensus is for FY23 revenue $1.01B. FY23 revenue view represents 23%-25% growth over 2022 revenue of $847.1M. Relative to total revenue guidance range of 23%-25% growth, the company expects growth our vascular business to be slightly above this range and growth in neuro business to be below this range.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on PEN: